Niki BioSolutions, Inc. (NIKI)
$2.08+2.46%Close
Snapshot
- 1 week
- -31.1%-29.6% vs SPY
- 1 month
- -55.9%-56.6% vs SPY
- Market cap
- $169.4K
- P/E
- negindustry 14.4
- P/B
- 0.0
- EV/EBITDA
- -0.1
- Short % float
- 27.3%
- Days to cover
- 1.0
- Short change
- +11.4%
Signal: Call, Regime, Alignment, Score, ATR trend, HiLo flip, Coil, Exhaustion, Topping · Technicals (EMA stack, slope, squeeze, stochastic, MACD-Z, DI+) · Price & returns: 3 months, Year to date, 1 year
Price & returns: 3 years, 5 years
Signal: Composite · Performance (Q-Score, Sharpe, Sortino, Calmar, CAGR, drawdown, alpha)
Signal evidence
Best Combo (today's action, held-out profit factor and family votes) · White Arrow (the call, its profit factor and closed trades) · Regime (today's regime and the regime model's profit factor) · Exhaustion (whether buyers or sellers are stretched today and the latest release)
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company
About
Niki BioSolutions, Inc. (NIKI). Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
SEC filingsCIK 1734005
Profile
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUS
CEOChung Yuen Huen
IPOJul 20
Employees1
Shares outstanding81.4K
Float53.6K
Free float65.8%
Websiteaptorumgroup.com
Key executives
- Chung Yuen HuenFounder, CEO & Executive Director
- Kwok Kuen WongHead of Finance
Earnings history
Loading earnings…
